cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.6kc7k6
title: Occurrence Download

description: A dataset containing 268806 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Pica pica (Linnaeus, 1758)",
 "Year 2024-2025"
 ]
}

 The dataset includes 268806 records from 70 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009933-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6bae98
title: Occurrence Download

description: A dataset containing 3078 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Newbouldia laevis (Beauverd) Seem."
 ]
}

 The dataset includes 3078 records from 166 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009951-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28219311
title: Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors

description: BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies. <b>Clinical Trial number:</b> NCT05471856 There are many different types of treatments available for patients with cancer. One type of treatment aims to use the patient’s own immune system to target and destroy the cancer, known as immunotherapy. BI 1703880 is a new drug that has been developed to activate the immune system for the treatment of cancer. This study is evaluating BI 1703880 for patients with advanced cancers based on its ability to destroy cancer cells in animal studies. BI 1703880 is being investigated on its own and in combination with another drug, ezabenlimab. The reason for testing these two drugs together is because sometimes cancer cells can become resistant to one type of immunotherapy, making proteins to “turn off” the immune response targeting the cancer. Similar to BI 1703880, ezabenlimab is also an immunotherapy. However, it turns the immune system on in a different way from BI 1703880, which means they may work together to produce a better anticancer result. The objective of the study is to determine a suitable dose of BI 1703880 alone and in combination with ezabenlimab and to see if any side effects occur.
DOI: 10.6084/m9.figshare.28219311.v1
title: Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors

description: BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies. <b>Clinical Trial number:</b> NCT05471856 There are many different types of treatments available for patients with cancer. One type of treatment aims to use the patient’s own immune system to target and destroy the cancer, known as immunotherapy. BI 1703880 is a new drug that has been developed to activate the immune system for the treatment of cancer. This study is evaluating BI 1703880 for patients with advanced cancers based on its ability to destroy cancer cells in animal studies. BI 1703880 is being investigated on its own and in combination with another drug, ezabenlimab. The reason for testing these two drugs together is because sometimes cancer cells can become resistant to one type of immunotherapy, making proteins to “turn off” the immune response targeting the cancer. Similar to BI 1703880, ezabenlimab is also an immunotherapy. However, it turns the immune system on in a different way from BI 1703880, which means they may work together to produce a better anticancer result. The objective of the study is to determine a suitable dose of BI 1703880 alone and in combination with ezabenlimab and to see if any side effects occur.
DOI: 10.15468/dl.h38azg
title: Occurrence Download

description: A dataset containing 18070 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Nyssa sylvatica Marshall"
 ]
}

 The dataset includes 18070 records from 280 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009952-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.25987929
title: Feasibility and Safety of Oral Risperidone to Treat Prehospital Agitation

description: Agitation is a common prehospital problem and frequently presents without a clear etiology. Given the dynamic environment of the prehospital setting, there has historically been a varied approach to treating agitation with a heavy reliance on parenteral medications. Newer best practice guidelines recommend the incorporation of oral medications to treat patients experiencing agitation. Therefore, we evaluated the use of oral risperidone in a single system after a change in protocol occurred. This was conducted as a retrospective chart review of an urban/suburban Emergency Medical Services system over the period of 8 months. The first day this medication was implemented throughout the service was included. Charts were included for selection if they included risperidone oral dissolving tablet (ODT) as a charted medication. The primary outcome was administration of additional medications to treat agitation. Exploratory outcome measures included acceptance of medication, documented injury to paramedics, documented injuries to patients, scene times, and adverse events that could possibly be linked to the medication. A total of 552 records were screened for inclusion. Risperidone was offered to 530 patients and accepted by 512 (96.6%). Of these 512 patients, the median age of included patients was 39 years old (IQR 29–52 years old) with a range of 18–89 years old. Rescue or additional medications for agitation were required in 9 (1.8%) cases. There were a total of 4 (0.8%) potential complications following administration of risperidone. There were no reported assaults with subsequent injuries to prehospital personnel or injuries sustained by patients reported in this study. Risperidone ODT was found to be a safe and effective medication to treat mild agitation in a large urban and suburban EMS system. The need for additional medications to treat agitation was rare, and there were no documented injuries to either patients or paramedics.
DOI: 10.6084/m9.figshare.25987929.v1
title: Feasibility and Safety of Oral Risperidone to Treat Prehospital Agitation

description: Agitation is a common prehospital problem and frequently presents without a clear etiology. Given the dynamic environment of the prehospital setting, there has historically been a varied approach to treating agitation with a heavy reliance on parenteral medications. Newer best practice guidelines recommend the incorporation of oral medications to treat patients experiencing agitation. Therefore, we evaluated the use of oral risperidone in a single system after a change in protocol occurred. This was conducted as a retrospective chart review of an urban/suburban Emergency Medical Services system over the period of 8 months. The first day this medication was implemented throughout the service was included. Charts were included for selection if they included risperidone oral dissolving tablet (ODT) as a charted medication. The primary outcome was administration of additional medications to treat agitation. Exploratory outcome measures included acceptance of medication, documented injury to paramedics, documented injuries to patients, scene times, and adverse events that could possibly be linked to the medication. A total of 552 records were screened for inclusion. Risperidone was offered to 530 patients and accepted by 512 (96.6%). Of these 512 patients, the median age of included patients was 39 years old (IQR 29–52 years old) with a range of 18–89 years old. Rescue or additional medications for agitation were required in 9 (1.8%) cases. There were a total of 4 (0.8%) potential complications following administration of risperidone. There were no reported assaults with subsequent injuries to prehospital personnel or injuries sustained by patients reported in this study. Risperidone ODT was found to be a safe and effective medication to treat mild agitation in a large urban and suburban EMS system. The need for additional medications to treat agitation was rare, and there were no documented injuries to either patients or paramedics.
DOI: 10.6084/m9.figshare.25962261
title: Association Between QRS Characteristics in Pulseless Electrical Activity and Survival Outcome in Cardiac Arrest Patients: A Systematic Review and Meta-Analysis

description: Recent studies have shown inconsistent results regarding the association between QRS characteristics and survival outcomes in patients with cardiac arrest and pulseless electrical activity (PEA) rhythms. This meta-analysis aimed to identify the usefulness of QRS width and frequency as prognostic tools for outcomes in patients with cardiac arrest and PEA rhythm. Extensive searches were conducted using Medline, Embase, and the Cochrane Library to find articles published from database inception to 4 June 2023. Studies that assessed the association between the QRS characteristics of cardiac arrest patients with PEA rhythm and survival outcomes were included. The Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. A total of 9727 patients from seven observational studies were included in this systematic review and meta-analysis. The wide QRS group (QRS ≥ 120 ms) was associated with significantly higher odds of mortality than the narrow QRS group (QRS &lt; 120 ms) (odds ratio (OR) = 1.86, 95% confidence interval (CI) = 1.11–3.11, <i>I</i><sup>2</sup> = 58%). The pooled OR for mortality was significantly higher in patients with a QRS frequency of &lt; 60/min than in those with a QRS frequency of ≥ 60/min (OR = 1.90, 95% CI = 1.19–3.02, <i>I</i><sup>2</sup> = 65%). Wide QRS width or low QRS frequency is associated with increased odds of mortality in patients with PEA cardiac arrest. These findings may be beneficial to guide the disposition of cardiac arrest patients with PEA during resuscitation.
DOI: 10.6084/m9.figshare.25962261.v1
title: Association Between QRS Characteristics in Pulseless Electrical Activity and Survival Outcome in Cardiac Arrest Patients: A Systematic Review and Meta-Analysis

description: Recent studies have shown inconsistent results regarding the association between QRS characteristics and survival outcomes in patients with cardiac arrest and pulseless electrical activity (PEA) rhythms. This meta-analysis aimed to identify the usefulness of QRS width and frequency as prognostic tools for outcomes in patients with cardiac arrest and PEA rhythm. Extensive searches were conducted using Medline, Embase, and the Cochrane Library to find articles published from database inception to 4 June 2023. Studies that assessed the association between the QRS characteristics of cardiac arrest patients with PEA rhythm and survival outcomes were included. The Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. A total of 9727 patients from seven observational studies were included in this systematic review and meta-analysis. The wide QRS group (QRS ≥ 120 ms) was associated with significantly higher odds of mortality than the narrow QRS group (QRS &lt; 120 ms) (odds ratio (OR) = 1.86, 95% confidence interval (CI) = 1.11–3.11, <i>I</i><sup>2</sup> = 58%). The pooled OR for mortality was significantly higher in patients with a QRS frequency of &lt; 60/min than in those with a QRS frequency of ≥ 60/min (OR = 1.90, 95% CI = 1.19–3.02, <i>I</i><sup>2</sup> = 65%). Wide QRS width or low QRS frequency is associated with increased odds of mortality in patients with PEA cardiac arrest. These findings may be beneficial to guide the disposition of cardiac arrest patients with PEA during resuscitation.
DOI: 10.15468/dl.qhewne
title: Occurrence Download

description: A dataset containing 2064 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Heteranthera reniformis Ruiz & Pav., Leptanthus peruvianus Pers., Heteranthera virginicus Steud., Pontederia azurea Schult. & Schult.f., Heteranthera acuta Willd., Heteranthera acuta Vahl, Buchozia aquatica Vell., Heteranthera reniformis var. conjungens O.Schwarz, Heteranthera pubescens Vahl, Buchosia aquatica Vell., Leptanthus virginicus Pers., Leptanthus reniformis (Ruiz & Pav.) Michx., Heterandra reniformis (Ruiz & Pav.) P.Beauv., Schollera reniformis (Ruiz & Pav.) Kuntze, Phrynium reniforme (Ruiz & Pav.) Kuntze, Phrynium reniforme var. acutum (Willd.) Kuntze)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000"
 ]
}

 The dataset includes 2064 records from 156 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009953-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.93wfsj
title: Occurrence Download

description: A dataset containing 326 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Registros de conflicto humano-fauna en Ecuador desde el año 2009 al 2022"
 ]
}

 The dataset includes 326 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009954-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.4h6ffh
title: Occurrence Download

description: A dataset containing 90732280 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON((-5.41407 33.95343,5.16011 35.21394,4.29593 33.94343,13.1525 29.75147,32.13134 29.0062,39.59775 34.5698,33.63892 41.3302,28.25794 43.2782,26.34105 41.53208,13.35771 46.34707,4.05924 44.20238,-5.77929 38.59063,-5.41407 33.95343))"
 ]
}

 The dataset includes 90732280 records from 7001 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009938-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/d4xj8a
title: A new species and typification in Pedicularis series Curvipes (Orobanchaceae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Agnihotri, Priyanka, Husain, Danish, Sahoo, Dinabandhu, Barik, Saroj Kanta (2018): A new species and typification in Pedicularis series Curvipes (Orobanchaceae). Phytotaxa 371 (4): 260-266, DOI: 10.11646/phytotaxa.371.4.3, URL: http://dx.doi.org/10.11646/phytotaxa.371.4.3AbstractPedicularis series Curvipes, of the family Orobanchaceae consisting of three species, is mainly distributed in eastern Himalaya, P. curvipes and P. nagaensis are found distributed from Sikkim to Manipur and P. amplicollis is reported from Bhutan. In the present study, a new taxon, closely related to P. amplicollis, is described from Dzükou valley, Manipur, and illustrated here as P. husainiana P.Agnihotri, D. Husain, D. Sahoo & S.K. Barik. Additionally, the lectotype of P. curvipes is designated here.
DOI: 10.15468/vhybz2
title: Aster sanqingensis (Asteraceae, Astereae), a synonym of Aster sanqingshanicus

description: This dataset contains the digitized treatments in Plazi based on the original journal article Xiao, Jia-Wei, Liu, Ting, Li, Wei-Ping, Yang, Xian-Jun (2023): Aster sanqingensis (Asteraceae, Astereae), a synonym of Aster sanqingshanicus. Phytotaxa 591 (1): 87-90, DOI: 10.11646/phytotaxa.591.1.11, URL: http://dx.doi.org/10.1094/PDIS-04-22-0755-PDN
DOI: 10.15468/s6pve9
title: Recent studies on terpenoids in Aspergillus fungi: Chemical diversity, biosynthesis, and bioactivity

description: This dataset contains the digitized treatments in Plazi based on the original journal article Zhao, Wen-Yu, Yi, Jing, Chang, Yi-Bo, Sun, Cheng-Peng, Ma, Xiao-Chi (2022): Recent studies on terpenoids in Aspergillus fungi: Chemical diversity, biosynthesis, and bioactivity. Phytochemistry (113011) 193: 1-25, DOI: 10.1016/j.phytochem.2021.113011, URL: http://dx.doi.org/10.1016/j.phytochem.2021.113011
DOI: 10.15468/exdebv
title: Xochiquetzallia magnifolia (Asparagaceae, Brodiaeoideae), a new species from Oaxaca, Mexico

description: This dataset contains the digitized treatments in Plazi based on the original journal article García-Mendoza, Abisaí Josué, Gutiérrez, Jorge (2022): Xochiquetzallia magnifolia (Asparagaceae, Brodiaeoideae), a new species from Oaxaca, Mexico. Phytotaxa 552 (3): 201-207, DOI: 10.11646/phytotaxa.552.3.4AbstractA recent exploration in Mixteca Alta, state of Oaxaca, and the morphological review of herbarium specimens allowed the identification of a new species of Xochiquetzallia, genus recently segregated from the paraphyletic Dandya. The objective of this work is to describe and illustrate Xochiquetzallia magnifolia, which can be recognized by its leaf size, scape, floral morphology, number of flowers per umbel, and inclined style. Due to its limited occurrence area and known distribution in one locality, it is considered vulnerable (VU) according to the guidelines of the International Union for Conservation of Nature (IUCN).
DOI: 10.15468/54ye43
title: A new species of the genus Nanosesarma Tweedie, 1950 (Crustacea: Decapoda: Brachyura: Sesarmidae) from India

description: This dataset contains the digitized treatments in Plazi based on the original journal article Trivedi, Jigneshkumar N., Padate, Vinay P., Ng, Peter K. L. (2024): A new species of the genus Nanosesarma Tweedie, 1950 (Crustacea: Decapoda: Brachyura: Sesarmidae) from India. Zootaxa 5433 (2): 289-298, DOI: 10.11646/zootaxa.5433.2.8, URL: http://dx.doi.org/10.11646/zootaxa.5433.2.8AbstractA new species of mangrove sesarmid crab, Nanosesarma gomantaka n. sp. is described on the basis of specimens collected from Chapora Estuary in Goa State, India. Nanosesarma gomantaka n. sp. closely resembles N. pontianacense (De Man, 1895) from Southeast and East Asia in having an elongated carapace, arcuate frontal lobes with a median notch and the presence of strong proximal spine on outer surface of male cheliped dactylus, but can be distinguished by the generally more arcuate frontal lobes with deep V-shaped median notch, the tip of the external orbital angle not extending beyond the rudimentary epibranchial tooth, and the proportionately more slender male first gonopod, with a straight distal portion bent at an obtuse angle.
DOI: 10.15468/d9d5qc
title: New Records of Chikunia subrapulum (Zhu, 1998), n. comb., (Araneae: Theridiidae) from Japan, with Taxonomical and Nomenclatural Notes

description: This dataset contains the digitized treatments in Plazi based on the original journal article Brindha, T R, Prabhu, K, Jones, Sumathi, Janaki, C S, Sheriff, Dhastangir, Kumar, Hayagreva Muttevi, Kalaivani, S, Lakshmi, Deepa (2023): New Records of Chikunia subrapulum (Zhu, 1998), n. comb., (Araneae: Theridiidae) from Japan, with Taxonomical and Nomenclatural Notes. Bulletin of the National Museum of Nature and Science. Series A, Zoology 49 (4): 123-127, DOI: 10.50826/bnmnszool.49.4_123, URL: http://dx.doi.org/10.4103/jpbs.jpbs_14_24Abstract Specimens of 53 females and 11 males of an unknown spider species from the family Theridiidae in Japan were taxonomically studied. The spider is identified as Chrysso subrapulum Zhu, 1998 known only from males from China, which is recorded here from Japan for the first time. This species is described based on the Japanese specimens, including hitherto unknown females, and is transferred from the original genus Chrysso O. Pickard Cambridge, 1882 to the genus Chikunia Yoshida, 2009 via a comparative examination of morphological characteristics. A nomenclatural problem with the specific name of this spider is discussed and its original spelling must be used for it.
DOI: 10.15468/dl.zs4waz
title: Occurrence Download

description: A dataset containing 47 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Aiouea formicaria"
 ]
}

 The dataset includes 47 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0064633-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18045244
title: ATACHOBA dataset
DOI: 10.5281/zenodo.18045243
title: ATACHOBA dataset
DOI: 10.15468/6anubm
title: Allium izmirense Pirhan, sp. nov. (Amaryllidaceae), a new species of Allium sect. Codonoprasum Rchb. from Turkey

description: This dataset contains the digitized treatments in Plazi based on the original journal article Pirhan, Ademi Fahri (2022): Allium izmirense Pirhan, sp. nov. (Amaryllidaceae), a new species of Allium sect. Codonoprasum Rchb. from Turkey. Adansonia (3) 44 (13): 133, DOI: 10.5252/adansonia2022v44a13ABSTRACTAllium izmirense Pirhan, sp. nov. (Amaryllidaceae) is described here as a new species. Diagnostic morphological characters, a full description, and detailed illustrations are given herein. Allium izmirense Pirhan, sp. nov. is restricted to Mt. Güme, a part of the Aydin Mountains series near the Tire District of İzmir Province in western Anatolia, Turkey. According to its morphological features, it belongs to Allium sect. Codonoprasum. It shows morphological similarities to A. carlstroemi C. Catt., A. stamineum Boiss., A. armenum Boiss., A. tchihatschewii subsp. dumanii (Koyuncu & Koçyigit) Yild., A. hoshabicum Firat, and A. huber-morathii Kollman, which belong to the same section. Allium izmirense sp. nov. is close related to A. carlstroemi. It is easily distinguished from this species mainly by its outer tunic papyraceous; cylindrical and pubescent leaves; leaf sheaths for 1/3-1/2 of the stem length; spathe shorter valves 0.5-1.4 cm long, longer valves 1.4-3(-6) cm long; pedicels length 0.5-1.5 cm; tepal pinkish purple, with distinct midrib, length 2.5-3.5 mm; style 2-3 mm long. According to the IUCN criteria A. izmirense Pirhan, sp. nov. is suggested as Critically Endangered (CR) B 2ab (ii,iii,v).
DOI: 10.5281/zenodo.18045369
title: Ultrasonic Wave Data for Bulk Hardness Prediction of Inconel 600
DOI: 10.5281/zenodo.18045368
title: Ultrasonic Wave Data for Bulk Hardness Prediction of Inconel 600